Do <i>MDM2</i> SNP309 and <i>TP53</i> R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium
Marjanka K. Schmidt(University of Cambridge), Laura J. van’t Veer(University of California, San Francisco), Thilo Dörk(Hannover Re (Germany)), Annegien Broeks, Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Alison M. Dunning(University of Cambridge), Douglas F. Easton(University of Cambridge), Scarlett Reincke(Medizinische Hochschule Hannover), Johanna Tommiska(Helsinki University Hospital), Heli Nevanlinna(University of Helsinki), Carl Blomqvist(University of Helsinki), Olivia Fletcher(Breast Cancer Care), Linde M. Braaf(The Netherlands Cancer Institute), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Frans B.L. Hogervorst(The Netherlands Cancer Institute), Nichola Johnson(Institute of Cancer Research), Catherine S. Healey(University of Cambridge), Julian Peto(London School of Hygiene & Tropical Medicine)
Cited by 79
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k